Literature DB >> 7920366

Urinary concentrations of fosfomycin after a single 3 g dose of fosfomycin to elderly nursing-home patients.

R Janknegt1, P M Hooymans, G T Fabius, M K Nohlmans-Paulssen, C Machielsen, J Boogaard-van den Born, J Rang, C A Smits, M E Willems-Thissen, A Krommenhoek.   

Abstract

The urinary concentrations of fosfomycin in 7 elderly patients with impaired renal function (mean creatinine clearance 40 ml/min) were studied after a single oral dose of 3 g fosfomycin as the trometamol salt. Urine samples were collected as 12 h portions for 84 h. Urinary concentrations of fosfomycin were 1,383 mg/l (range 314 to 4,200 mg/l) in the first 12 h and gradually declined to 165 mg/l (range 65 to 365 mg/l) between 36 and 48 h. 37% of the oral dose was recovered in the urine unchanged after 84 h, but a wide range (15-60%) in urinary recovery was observed. The elimination half-lives in the patients (estimated from the renal excretion profile of fosfomycin) ranged between 7 and 24 h. These data suggest that the urinary levels obtained in this patient population exceed the minimum inhibiting concentration of the usual pathogens involved in uncomplicated cystitis for at least 48 h. After 24 h the urinary concentrations of fosfomycin are higher than those reported for healthy young subjects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7920366     DOI: 10.1007/bf01877485

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  10 in total

1.  Pharmacokinetics of amoxycillin in elderly in-patients.

Authors:  R Janknegt; J Boogaard-Van den Born; B A Hameleers; P M Hooymans; J Rang; C A Smits; M E Willems-Thissen
Journal:  Pharm Weekbl Sci       Date:  1992-02-21

2.  Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients.

Authors:  M B O'Connell; A M Dwinell; S D Bannick-Mohrland
Journal:  Ann Pharmacother       Date:  1992-05       Impact factor: 3.154

3.  Letter: Creatinine clearance: bedside estimate.

Authors:  R W Jelliffe
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

4.  Antibacterial activity of fosfomycin trometamol in the urine after simulation of oral doses in a pharmacokinetic in vitro model.

Authors:  B Wiedemann; M Groos
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

5.  In vitro susceptibility testing procedures for fosfomycin tromethamine.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

6.  The trometamol salt of fosfomycin: microbiological evaluation.

Authors:  D Greenwood; S Coyle; J Andrew
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

7.  Pharmacokinetic profile of fosfomycin trometamol (Monuril).

Authors:  G Segre; E Bianchi; A Cataldi; G Zannini
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

8.  Correlation between bactericidal activity of fosfomycin trometamol in an in vitro model of the urinary bladder and susceptibility testing.

Authors:  C Pinasi; E Albini; G Marca
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

9.  Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction.

Authors:  E Bergogne-Bérézin; C Muller-Serieys; M L Joly-Guillou; N Dronne
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

10.  Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/co-trimoxazole.

Authors:  K G Naber; U Thyroff-Friesinger
Journal:  Infection       Date:  1992       Impact factor: 3.553

  10 in total
  5 in total

Review 1.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

Review 3.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 4.  Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Authors:  S S Patel; J A Balfour; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

5.  Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

Authors:  Sander G Kuiper; Anneke C Dijkmans; Erik B Wilms; Ingrid M C Kamerling; Jacobus Burggraaf; Jasper Stevens; Cees van Nieuwkoop
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.